D
Deb K. Pal
Researcher at King's College London
Publications - 133
Citations - 4611
Deb K. Pal is an academic researcher from King's College London. The author has contributed to research in topics: Epilepsy & Rolandic epilepsy. The author has an hindex of 33, co-authored 121 publications receiving 3963 citations. Previous affiliations of Deb K. Pal include Boston Children's Hospital & Child In Need Institute.
Papers
More filters
Journal ArticleDOI
Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes
Johannes R. Lemke,Dennis Lal,Eva M. Reinthaler,Isabelle Steiner,Michael Nothnagel,Michael Alber,Kirsten Geider,Bodo Laube,Michael Schwake,Katrin Finsterwalder,Andre Franke,Markus Schilhabel,Johanna A. Jähn,Hiltrud Muhle,Rainer Boor,Wim Van Paesschen,Roberto Caraballo,Natalio Fejerman,Sarah Weckhuysen,Peter De Jonghe,Jan Larsen,Rikke S. Møller,Helle Hjalgrim,Laura Addis,Shan Tang,Elaine Hughes,Deb K. Pal,Kadi Veri,Ulvi Vaher,Tiina Talvik,Petia Dimova,Rosa Guerrero López,José M. Serratosa,Tarja Linnankivi,Anna-Elina Lehesjoki,Susanne Ruf,Markus Wolff,Sarah E. Buerki,Gabriele Wohlrab,Judith Kroell,Alexandre N. Datta,Barbara Fiedler,Gerhard Kurlemann,Gerhard Kluger,Andreas Hahn,D Edda Haberlandt,Christina Kutzer,Jürgen Sperner,Felicitas Becker,Yvonne G. Weber,Martha Feucht,Hannelore Steinböck,Birgit Neophythou,Gabriel M. Ronen,Ursula Gruber-Sedlmayr,Julia Geldner,Robert J. Harvey,Per Hoffmann,Per Hoffmann,Stefan Herms,Stefan Herms,Janine Altmüller,Mohammad R. Toliat,Holger Thiele,Peter Nürnberg,Christian Wilhelm,Ulrich Stephani,Ingo Helbig,Holger Lerche,Fritz Zimprich,Bernd A. Neubauer,Saskia Biskup,Saskia Biskup,Sarah von Spiczak +73 more
TL;DR: Results establish alterations of the gene encoding the NMDA receptor NR2A subunit as a major genetic risk factor for IFE.
Journal ArticleDOI
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction.
Gaetan Lesca,Gabrielle Rudolf,Nadine Bruneau,Natalia Lozovaya,Audrey Labalme,Nadia Boutry-Kryza,Manal Salmi,Timur Tsintsadze,Laura Addis,Jacques Motte,Sukhvir Wright,Vera Tsintsadze,Vera Tsintsadze,Vera Tsintsadze,Anne Michel,Diane Doummar,Karine Lascelles,Lisa J. Strug,Patrick Waters,Julitta de Bellescize,Pascal Vrielynck,Anne de Saint Martin,Dorothée Ville,Philippe Ryvlin,Alexis Arzimanoglou,Edouard Hirsch,Angela Vincent,Deb K. Pal,Nail Burnashev,Damien Sanlaville,Pierre Szepetowski +30 more
TL;DR: It is demonstrated that about 20% of cases of LKS, CSWSS and electroclinically atypical rolandic epilepsy often associated with speech impairment can have a genetic origin sustained by de novo or inherited mutations in the GRIN2A gene (encoding the N-methyl-D-aspartate (NMDA) glutamate receptor α2 subunit, GluN2A).
Journal ArticleDOI
Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4)
Lisa J. Strug,Tara Clarke,Theodore Chiang,Minchen Chien,Zeynep Baskurt,Weili Li,Ruslan Dorfman,Bhavna Bali,Elaine C. Wirrell,Steven L. Kugler,David E. Mandelbaum,Steven M Wolf,Patricia McGoldrick,Huntley Hardison,Edward J. Novotny,Jingyue Ju,David A. Greenberg,David A. Greenberg,James J. Russo,Deb K. Pal,Deb K. Pal +20 more
TL;DR: It is hypothesized that a non-coding mutation in ELP4 impairs brain-specific Elongator-mediated interaction of genes implicated in brain development, resulting in susceptibility to seizures and neurodevelopmental disorders.
Journal ArticleDOI
BRD2 (RING3) Is a Probable Major Susceptibility Gene for Common Juvenile Myoclonic Epilepsy
TL;DR: The findings strongly suggest that BRD2 (RING3) is EJM1, the first gene identified for a common idiopathic epilepsy, and the findings have implications for the generalizability of proposed pathogenetic mechanisms, derived from diseases that show Mendelian transmission to their complex counterparts.
Journal ArticleDOI
Neurocysticercosis and epilepsy in developing countries
TL;DR: There is a dilemma about whether limited public resources would better be spent on general economic development, which would be expected to have a broad impact on the health and welfare of communities, or on specific programmes to help individual affected people with neurocysticercosis and epilepsy.